Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022 NKX019 Phase 1 clinical trial recently opened dose expansion cohorts NKX019 clinical update is expected by year-end 2022 NKX101 …